top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


Succession Planning in Life Sciences: Your Most Overlooked Risk Management Tool
Succession planning in the life sciences industry is not a “nice to have” HR process—it’s a core element of risk management and business continuity. Unplanned leadership gaps can delay clinical trials, regulatory submissions, manufacturing, and product launches, directly impacting patients and revenue. In this article, we explore when, why and how life sciences organisations should approach leadership succession, the mission‑critical roles to prioritise, and practical steps.
sharonshieldsconsu
Nov 73 min read


Remember, Remember the Fifth of November: Biotech’s Fireworks, Sparks and Slow Burns
Remember, remember the fifth of November—the night when bonfires burn, fireworks light the sky and everyone looks up to see what will explode next. Biotech has its own Fireworks Night. This year’s display featured headline-grabbing rockets: GLP‑1 deals, gene editing milestones, renewed enthusiasm for RNA and a more disciplined wave of AI‑in‑drug‑discovery stories. But, as every investor knows, not everything that launches reaches the same height.
For biotech insiders and inv
sharonshieldsconsu
Nov 53 min read


How AI Is Transforming Clinical Development Drug Discovery Recruitment and Trial Management
Clinical development has always carried a painful contradiction. Science can point to promising biology, yet turning that promise into a tested therapy can take years of trial design, patient matching, site coordination and regulatory work. Many compounds fail late. Many trials struggle to enrol. Many teams spend too much time searching for patterns that sit hidden in papers, scans, genomic files and electronic health records.
sharonshieldsconsu
Oct 239 min read


The Three Things VCs Are Really De‑Risking
Most platform biotechs don’t fail on science—they fail because investors don’t believe the team can turn that science into a real, defensible engine. This post breaks down what VCs are actually trying to de‑risk in a platform biotech, how your first five hires map to those concerns, and the concrete artifacts (org map, hiring plan, scorecards, RA/QA and BD thinking) you can bring to a pitch to show you’re building a fundable team, not just a cool idea.
sharonshieldsconsu
Aug 227 min read
bottom of page